JW (Cayman) Therapeutics Co. Ltd
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabt… Read more
Market Cap & Net Worth: JW (Cayman) Therapeutics Co. Ltd (JWCTF)
JW (Cayman) Therapeutics Co. Ltd (PINK:JWCTF) has a market capitalization of $67.43 Million ($67.43 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #21095 globally and #7591 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying JW (Cayman) Therapeutics Co. Ltd's stock price $0.16 by its total outstanding shares 416232634 (416.23 Million).
JW (Cayman) Therapeutics Co. Ltd Market Cap History: 2021 to 2025
JW (Cayman) Therapeutics Co. Ltd's market capitalization history from 2021 to 2025. Data shows change from $828.30 Million to $67.43 Million (-53.73% CAGR).
JW (Cayman) Therapeutics Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how JW (Cayman) Therapeutics Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.67x
JW (Cayman) Therapeutics Co. Ltd's market cap is 0.67 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $828.30 Million | $30.80 Million | -$702.33 Million | 26.90x | N/A |
| 2022 | $209.74 Million | $145.70 Million | -$846.13 Million | 1.44x | N/A |
| 2023 | $111.22 Million | $173.86 Million | -$768.00 Million | 0.64x | N/A |
| 2024 | $106.14 Million | $158.22 Million | -$590.62 Million | 0.67x | N/A |
Competitor Companies of JWCTF by Market Capitalization
Companies near JW (Cayman) Therapeutics Co. Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to JW (Cayman) Therapeutics Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
JW (Cayman) Therapeutics Co. Ltd Historical Marketcap From 2021 to 2025
Between 2021 and today, JW (Cayman) Therapeutics Co. Ltd's market cap moved from $828.30 Million to $ 67.43 Million, with a yearly change of -53.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $67.43 Million | -36.47% |
| 2024 | $106.14 Million | -4.57% |
| 2023 | $111.22 Million | -46.97% |
| 2022 | $209.74 Million | -74.68% |
| 2021 | $828.30 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of JW (Cayman) Therapeutics Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $67.43 Million USD |
| MoneyControl | $67.43 Million USD |
| MarketWatch | $67.43 Million USD |
| marketcap.company | $67.43 Million USD |
| Reuters | $67.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.